Related Experiment Video

Updated: May 25, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

252

Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer

Jing Liu1,2, Zhihao Zhao1, Richard Zanni1

  • 1Department of Chemistry, University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, United States.

ACS Nano
|February 26, 2025
PubMed

Insights

This study introduces PPA/HG nanoparticles for dual CD47 and PD-L1 blockade cancer immunotherapy. This novel approach effectively targets tumors, enhancing immune response while minimizing side effects.

Area of Science:

  • Immunology
  • Nanotechnology
  • Oncology

Background:

  • Dual blockade of CD47 and PD-L1 checkpoints shows cancer treatment potential.
  • Monoclonal antibodies face limitations due to on-target, off-tumor immunotoxicities.

Purpose of the Study:

  • To develop a novel core-shell nanoparticle, PPA/HG, for potent cancer immunotherapy.
  • To overcome the limitations of traditional antibody therapies by achieving targeted immune checkpoint blockade.

Main Methods:

  • Synthesized a core-shell nanoparticle (PPA/HG) with polyinosinic:polycytidylic acid (PPA) core and a cholesterol-conjugated 3-(hydroxyolinoyl)glycine (HG) shell.
  • Investigated HG's mechanism in downregulating CD47 and PD-L1 via histone lysine demethylase 3A/c-Myc pathway.
  • Assessed PPA's role in activating toll-like receptor 3 (TLR3) in immune cells for enhanced anti-tumor immunity.

Main Results:

  • PPA/HG demonstrated a long blood half-life, enabling efficient tumor accumulation and drug release.
  • HG effectively downregulated CD47 and PD-L1 on cancer cells; PPA promoted dendritic cell maturation and macrophage repolarization.
  • PPA/HG enhanced effector T cell infiltration and activation while reducing regulatory T cells, significantly inhibiting tumor progression in preclinical models.

Conclusions:

  • PPA/HG nanoparticles offer a promising strategy for dual CD47 and PD-L1 immune checkpoint blockade.
  • This nanoparticle system effectively reprograms the tumor microenvironment, enhancing anti-tumor immunity with minimal toxicity.
  • PPA/HG shows significant potential for treating aggressive cancers like triple-negative breast cancer and pancreatic ductal adenocarcinoma.
Keywords:
cancer immunotherapycluster of differentiation 47histone lysine demethylase 3Ananoscale coordination polymerprogrammed cell death-ligand 1toll-like receptor 3

More Related Videos

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.3K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

563

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
462
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
826
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
325
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K